Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A*STAR's GIS Collaborates with GSK to Further Research on Lung Cancer

Published: Thursday, January 31, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Partnership will advance both organizations' joint efforts towards finding a cure for the disease.

In a latest boost to A*STAR's collaborations with the industry, Dr Bing LIM, Associate Director of Cancer Stem Cell Biology, and Senior Group Leader at the Genome Institute of Singapore (GIS), was recently awarded a GlaxoSmithKline (GSK) grant under the Academic Centre of Excellence (ACE) to further his research on lung cancer at the GIS.

This partnership between GIS and GSK, a multinational pharmaceutical, biologics, vaccines and consumer healthcare company which administers the ACE in Singapore, will significantly advance both organizations' joint efforts towards finding a cure for the disease.

The central goal of this grant awarded to GIS, worth SGD$350,000, is the identification of new diagnostic and therapeutic targets for cancer, and the initiation of a commit-to-target (C2T) milestone in GSK discovery. A three-pronged approach will be adopted in order to achieve this.

Leveraging on GIS' successes in identifying and characterizing lung cancer tumour initiating cells, and hence allowing for the identification of new diagnostic and therapeutic targets in lung cancer, the first of the three-pronged approach is to fully validate these targets as candidates for discovery initiation, focusing on those that are amenable to bio-therapeutics.

The second stage of the grant will focus on using high-throughput sequencing technologies to sequence the lung cancer cells and identify unique and novel variant tumors markers, which could be used as diagnostic and therapeutic targets in cancers.

The third stage involves the full characterization of monoclonal antibodies that have been generated by GIS against lung cancer cells that are highly enriched for cancer tumor initiating cells.

Dr Bing LIM said, "This collaboration with GSK provides a great opportunity for both parties to learn what the most effective way is for industry and academic research to join forces in the constantly changing landscape of scientific paradigm, biomedical technology and health care goals."

Executive Director of GIS, Prof NG Huck Hui said, "Prof Bing Lim's lab is doing cutting-edge research in lung cancer initiating cells and the award of this ACE grant is a clear endorsement of the translational value of his research. This is an exemplar of how world class research done at the Biopolis is attracting industry interest and building strategic alliance."

Dr Benjamin SEET, Executive Director of the Biomedical Research Council at A*STAR added, "This partnership is an example of the value proposition we seek to create here in Biopolis. It brings together a leading scientist with a pharmaceutical company, with the aim of taking a scientific discovery closer to the clinic, and finding new cures for a disease that is currently difficult to treat".


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Advancing the Understanding and Research of Botulinum Neurotoxin Biology
Ipsen and the Institute of Molecular and Cell Biology (IMCB) announce the signature of a research partnership to study the intracellular trafficking of botulinum neurotoxins (BoNTs) within neurons.
Monday, May 16, 2016
A*STAR Findings on Breast Cancer Hold Potential for New Treatments
Computational techniques to increase understanding of diseases and improve patient treatments.
Friday, October 30, 2015
Rapid Test Kit Detects Dengue Antibodies from Saliva
IBN’s MedTech innovation simplifies diagnosis of infectious diseases.
Friday, January 30, 2015
A*STAR Scientists Discover Gene Critical for Proper Brain Development
This gene accounts for the size of the human brain and potentially our superior cognitive abilities.
Friday, December 26, 2014
A Gold Catalyst for Clear Water
Mixed nanoparticle systems may help purify water and generate hydrogen.
Wednesday, December 24, 2014
Anti-Diabetic Drug Springs New Hope for Tuberculosis Patients
Drug for treating diabetes can double up as adjunct treatment for tuberculosis.
Wednesday, December 17, 2014
Gene Associated with an Aggressive Breast Cancer Identified
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment.
Wednesday, December 03, 2014
Diagnostics Development Hub To Complement Biomed Research Launched
Hub will leverage strategic public-public and public-private partnerships to accelerate market readiness of locally developed diagnostic products.
Friday, November 28, 2014
Protecting the Body from Itself
Scientists advance understanding of autoimmunity with discovery of link between major immune cell types.
Friday, September 26, 2014
Colorful Nanoprobes Make A Simple Test
Gold nanoparticles linked to single-stranded DNA create a simple but versatile genetic testing kit.
Thursday, September 25, 2014
Lab on a Breathing Chip
Human nasal epithelial cells, cultured on a microchip, react to air pollutants just like they would in the upper airway.
Saturday, September 13, 2014
Understanding and Improving the Body's Fight Against Pathogens
A*STAR scientists find new targets for modulating antibody response.
Tuesday, September 02, 2014
Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy
A predictive marker discovered by scientists at A*STAR and NUS could help doctors classify breast cancer patients for more effective treatment.
Thursday, August 21, 2014
High Capacity Antibody Purification
Researchers from the A*Star Bioprocessing Technology Institute have used magnetic nanoparticles to break the capacity barrier for antibody purification.
Sunday, August 17, 2014
New Tool to Study Critical Protein Interaction in Cancer Research
A*STAR scientists used fluorescent molecular rotors to study protein-protein interactions involving p53 and MDM2 in cells.
Thursday, July 03, 2014
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!